Therapeutic inhibition of platelet function in stroke

Cerebrovascular Diseases

Volumn 8, Issue SUPPL. 5, 1998, Pages 8-18

  Harker, Laurence A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiplatelet therapies; Aspirin; Clopidogrel; Dipyridamole; Ischemic stroke; Ticlopidine

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; INTEGRIN; THROMBIN; THROMBOXANE A2; TICLOPIDINE;

BLEEDING; CONFERENCE PAPER; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SIDE EFFECT; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION;

EID: 0031721148     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000047513     Document Type: Conference Paper

References (83)

1. Harker LA, Mann KG: Thrombosis and fibrinolysis; in Verstraete M, Fuster V, Topol EJ (eds): Cardiovascular Thrombosis: Thrombocardiology, ed 2. Philadelphia, Lippincott-Raven, 1998, pp 3-22.
2. Antiplatelet Trialists' Collaboration: Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106.
3. Antiplatelet Trialists' Collaboration: Collaborative overview of randomised trials of antiplatelet therapy. II. Maintenance of vascular graft or arterial patency by antiplatelet therapy. Br Med J 1994;308:159-168.
4. CAPRIE Steering Committee: A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemia. Lancet 1996;348: 1329-1339.
5. Harker LA: Platelets and vascular thrombosis. N Engl J Med 1994;330:1006-1007.
6. The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961.
7. 2 and prostacyclin. Pharmacol Rev 1978;30:293-331.
8. Smith WL, Garavito RM, DeWitt DL: Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996;271: 33157-33160.
9. Patrono C, Ciabattoni G, Patrignani P: Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985;72:1177-1184.
10. Pedersen AK, FitzGerald GA: Dose-related kinetics of aspirin: Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311:1206-1211.
11. Barry OP, Patrico D, Lawson JA, FitzGerald GA: Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest 1997;99:2118-2127.
12. 2 but not systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991;325:1137-1141.
13. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, Brace LD: Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994;25: 2331-2336.
14. Helgason CM, Hoff JA, Kondos GT, Brace LD: Platelet aggregation in patients with atrial fibrillation taking aspirin or Warfarin. Stroke 1993;24:1458-1461.
15. Buchanan MR, Brister SJ: Individual variation in the effects of ASA on platelet function: Implications for the use of ASA clinically. Can J Cardiol 1995;11:221-227.
16. Roth GJ, Stanford N, Majerus PW: Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci USA 1975;72:3073-3077.
17. Burch JW, Stanford PW, Majerus PW: Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1979;61:314-319.
18. Lindblad B, Persson NH, Takolander R: Does low-dose acetylsalicylic acid prevent stroke after carotid surgery? A double-blind, placebo-controlled randomized trial. Stroke 1993;24: 1125-1128.
19. Dutch TIA Trial Study Group: A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325:1261-1266.
20. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
21. McKenna R, Galante J, Bachmann F: Prevention of venous thrombo-embolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. Br Med J 1980;280:514-517.
22. Lewis HD, Davis JW, Archibald DG: Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: Results of a Veterans Administration Co-operative Study. N Engl J Med 1983;309:396-403.
23. Murata T, Ushikubi F, Matsuoka T: Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997;388:678-682.
24. Roth GJ, Calverley DC: Aspirin, platelets, and thrombosis: Theory and practice. Blood 1994; 83:885-898.
25. IST Collaborative Group: The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischemic stroke. Lancet 1997;349:1569-1581.
26. CAST Collaborative Group: Chinese Acute Stroke Trial (CAST): Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischemic stroke. Lancet 1997;349:1641-1649.
27. van Kooten F, Ciabattoni G, Patrono C, Schmitz PIM, van Gijn J, Koudstaal PJ: Evidence for episodic platelet activation in acute ischemic stroke. Stroke 1994;25:278-281.
28. van Kooten F, Ciabattoni G, Patrono C, Dippel DWJ, Koudstaal PJ: Platelet activation and lipid peroxidation in patients with acute ischemic stroke. Stroke 1997;28:1557-1563.
29. FitzGerald GA: Review on dipyridamole. N Engl J Med 1987;316:1247-1257.
30. Muller TH, Su CAPF, Weisenberger H, Brickl R, Nehmiz G, Eisert WG: Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharm 1990;30:179-186.
31. Hirsh J, Dalen JE, Fuster V, Harker LA, Patrono C, Roth G: Aspirin and other platelet-active drugs: The relationship among dose, effectiveness, and side effects. Chest 1995; 108(suppl 4):247S-257S.
32. Roth GJ, Majerus PW: The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975;56:624-632.
33. Herbert JM, Frechel D, Vallee E: Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev 1993;11:180-198.
34. Herbert JM, Tissinier A, Defreyn G, Maffrand JP: Inhibitory effect of clopidogrel on platelet adhesion and intimal proliferation following arterial injury in rabbits. Arterioscler Thromb 1993;13:1171-1179.
35. Savi P, Combalbert J, Graich C, Rouchon MC, Maffrand JP, Berger Y, Herbert JM: The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost 1994;72: 313-317.
36. Mills DCB, Puri R, Hu C-J, Minniti C, Grana G, Freedman MD, Colman RF, Colman RW: Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992;12:430-436.
37. 3H]-2-methyl-thioADP to rat platelets: Effect of clopidogrel and ticlopidine. J Pharmacol Exp Ther 1994;269:772-777.
38. Ito MK, Smith AR, Lee ML: Ticlopidine: A new platelet aggregation inhibitor. Clin Pharm 1992;11:603-617.
39. Balsano F, Rizzon P, Violi F, Scrutinio D, Cimminiello C, Aguglia F, Pasotti C, Rudelli G: Antiplatelet treatment with ticlopidine in unstable angina: A controlled multicenter clinical trial. Circulation 1990;82:17-26.
40. Hass WK, Easton JD, Adams HP: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321: 501-507.
41. Gent M, Blakely JA, Easton JD: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989;i:1215-1220.
42. FitzGerald GA: Ticlopidine in unstable angina: A more expensive aspirin? Circulation 1990;82:296-298.
43. Savi P, Heilmann E, Nurden P: Clopidogrel: An antithrombotic drug acting on the ADP-dependent activation pathway of human platelets. Clin Appl Thromb/Hemost 1996;2:35-42.
44. Lecompte TP, Lecrubier C, Bouloux C: Antiplatelet effects of the addition of acetylsalicylic acid 40 mg daily to ticlopidine in human healthy volunteers. Clin Appl Thromb/Hemost 1997;3:245-250.
45. Van Belle E, McFadden EP, Lablanche JM, Bauters C, Harmon M, Bertrand ME: Two-pronged antiplatelet therapy with aspirin and ticlopidine without systemic anticoagulation: An alternative therapeutic strategy after bail-out stent implantation. Coronary Artery Dis 1995;6:341-345.
46. Jordan C, Carvalho H, Fajadet J, Cassagneau B, Robert G, Marco J: Reduction of subacute thrombosis rate after coronary stenting using a new anticoagulant protocol (abstract). Circulation 1994;90:I-125.
47. Morice MC, Zemour G, Benveniste E, Biron Y, Bourdonnec C, Faivre R, Fajadet J, Gaspard P, Glatt B, Joly P, Labrunie P, Lienhart Y, Marco J, Petiteau P, Royer T, Valeix B: Intracoronary stenting without coumadin: One month results of a French multicenter study. Catheterization Cardiovasc Diagn 1995;35:1-7.
48. Harker LA, Hanson SR: Experimental strategies for assessing antithrombotic benefits and hemorrhagic risks of novel antithrombotic agents; in Sasahara A, Loscalzo J (eds): New Therapeutic Agents in Thrombosis and Thrombolysis. New York, Dekker, 1997, pp 29-48.
49. Lefkovits J, Plow EF, Topol EJ: Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995;332:1553-1559.
50. Coller BS: Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics. J Clin Invest 1997;99:1467-1471.
51. Coller BS, Peerschke EI, Scudder LE, Sullivan CA: A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983;72:325-338.
52. Tcheng JE, Ellis SG, George BS: Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90: 1757-1764.
53. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE: Pharmacodynamic profile of a short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998;97:1680-1688.
54. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M: Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. The EPIC Investigators. Lancet 1994;343:881-886.
55. EPILOG Investigators: Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
56. Kereiakes DJ, Essel JH, Abbottsmith CW, Broderick TM, Runyon JP: Abciximab-associated profound thrombocytopenia: Therapy with immunoglobulin and platelet transfusion. Am J Cardiol 1996;78:1161-1163.
57. Berkowitz SD, Harrington RA, Rund MM, Tcheng JE: Acute profound thrombocytopenia following c7E3 Fab (abciximab) therapy. Circulation 1997;95:809-813.
58. Hartman GD, Egbertson MS, Halczenko W: Non-peptide fibrinogen receptor antagonists. I. Discovery and design of exosite inhibitors. J Med Chem 1992;35:4640-4642.
59. Egbertson MS, Chang CT-C, Duggan ME, Gould RJ, Halczenko W, Hartman GD, Laswell WL, Lynch JJ Jr, Lynch RJ, Manno PD, Naylor AM, Prugh JD, Ramjit DR, Sitko GR, Smith RS, Turchi LM, Zhang G: Non-peptide fibrinogen receptor antagonists. 2. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp. J Med Chem 1994;37:2537-2551.
60. Barrett JS, Murphy G, Peerlinck K: Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/ IIIa receptor antagonist, in healthy men. Clin Pharmacol Ther 1994;56:377-388.
61. Peerlinck K, De Lepeleire I, Goldberg M, Farrell D, Barrett J, Hand E, Panebianco D, Deckmyn H, Vermylen J, Arnout J: MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation 1993;88:1512-1517.
62. Kereiakes DJ, Kleiman NS, Ambrose J: Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996;27:536-542.
63. Bednar B, Bednar RA, Cook JJ: Drug-dependent antibodies against GPIIb/IIIa induce thrombocytopenia. Circulation 1996;94:1-99.
64. Scarborough RM, Naughton MA, Teng W: Design of potent and specific integrin antagonists: Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J Biol Chem 1993;268: 1066-1073.
65. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJ, Miller JA, Joseph DM, Sigmon KN, Kitt MM, du Mee CP, Califf RM, Topol EJ: Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/ IIIa blocker integrelin in elective coronary intervention. Circulation 1995;91:2151-2157.
66. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS: Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: Potential implications for effect of c7E3 Fab treatment on acute thrombosis and 'clinical restenosis'. J Clin Invest 1996;98:863-874.
67. Harrington RA, Kleiman NS, Kottke Marchant K: Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous intervention. Am J Cardiol 1995; 76:1222-1227.
68. Lincoff AM, Harrington RA, Califf RM: Clinical efficacy of integrilin in unstable angina is accompanied by a modest increase in hemorrhagic risk: The PURSUIT Trial (abstract). J Am Coll Cardiol 1998;31 (suppl A): 185A.
69. McClure M, Kleiman NS, Berdan LG: Thrombocytopenia in a large, international trial of the GPIIb/IIIa inhibitor eptifibatide in patients with acute coronary syndromes (abstract). J Am Coll Cardiol 1998;31(suppl A):93A.
70. Alig L, Edenhofer A, Hadvary P: Low molecular weight, non-peptide fibrinogen receptor antagonists. J Med Chem 1992;35:4393-4407.
71. Carteaux JP, Steiner B, Roux S: Ro 44-9883, a new non-peptide GPIIb/IIIa antagonist prevents platelet loss in a guinea pig model of extracorporeal circulation. Thromb Haemost 1993;70:817-821.
72. Carroll RC, Steiner B, Kouns WC: The effects of Ro 43-5054 and Ro 44-9883, peptidometic inhibitors of the GPIIb/IIIa fibrinogen binding site on platelet stimulus-response coupling (abstract). Thromb Haemost 1993;69:785.
73. Theroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis J-F, Nasmith J, Fung AY, Boudreault J-R, Delage F, Dupuis R, Kells C, Bokslag M, Steiner B, Rapold HJ: Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: The Canadian lamifiban study. Circulation 1996;94:899-905.
74. IMPACT-11 Investigators: Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997;349:1422-1428.
75. RESTORE Investigators: Efefcts of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-1453.
76. CAPTURE Investigators: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429-1435.
77. Simpfendorfer C, Kottke-Marchant K, Lowrie M: First chronic platelet glycoprotein IIb/IIIa integrin blockade: A randomized, placebo-controlled study of xemilofiban in unstable angina with percutaneous coronary interventions. Circulation 1997;96:76-81.
78. Cannon CP: Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: Results of the TIMI-12 trial. Circulation 1998; 97:340-349.
79. Vorchheimer DA, Fuster V: Oral platelet glycoprotein IIb/IIIa receptor antagonists: The present challenge is safety. Circulation 1998; 97:312-314.
80. Coller BS: Monitoring platelet GP IIb/IIIa antagonist therapy. Circulation 1998;97:5-9.
81. Harker LA, Maraganore JM, Hirsh J: Novel antithrombotic agents; in Colman RW, Hirsh J, Marder VJ, Salzman EW (eds): Hemostasis and Thrombosis: Basic Principles and Clinical Practice, ed 3. Philadelphia, Lippincott, 1994, vol 86, pp 1638-1660.
82. Harker LA, Hanson SR, Kelly AB: Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation. Thromb Haemost 1997;78:736-741.
83. Jang Y, Guzman LA, Lincoff AM, Gottsauner-Wolf M, Forudi F, Hart CE, Courtman DW, Ezban M, Ellis SG, Topol EJ: Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation 1995; 92:3041-3050.